Hanmi Inks Record Korean Deal, With Boehringer For Cancer Therapy
This article was originally published in PharmAsia News
Executive Summary
Hanmi Pharmaceutical continues to lead South Korean pharma innovators by reaching a series of major licensing out deals. Following the major agreement with Lilly for its oral Bruton's tyrosine kinase inhibitor earlier this year, Hanmi has now inked an even bigger license agreement with Boehringer Ingelheim, for a novel non-small cell lung cancer therapy HM61713 that will beef up the German firm's oncology portfolio.
You may also be interested in...
Korean Pharmas To Highlight Lung Cancer Pipeline Progress At AACR
Several South Korean companies are set to present updates on their growing lung cancer pipelines at a major meeting in Chicago this month, underlining the high unmet needs and strong R&D interest in this area by firms in the country.
Hanmi’s Case: One Failure Doesn’t Speak For All
Since Boehringer Ingelheim’s u-turn on its lung cancer partnership with Hanmi Pharmaceutical, the South Korean company has seen its stock prices falling and latterly a government investigation. Confidence in the country’s burgeoning drug development industry has taken a hit but there are still plenty of reasons to believe in the country’s R&D engine.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.